

Robert L Ali

List of Publications by Year in Descending Order

Source: <https://exaly.com/author-pdf/8572464/robert-l-ali-publications-by-year.pdf>

Version: 2024-04-11

This document has been generated based on the publications and citations recorded by exaly.com. For the latest version of this publication list, visit the link given above.

The third column is the impact factor (IF) of the journal, and the fourth column is the number of citations of the article.

155 papers	7,309 citations	41 h-index	83 g-index
166 ext. papers	8,422 ext. citations	4.5 avg, IF	5.94 L-index

#	Paper	IF	Citations
155	The Drug Survey App: A protocol for developing and validating an interactive population survey tool for drug use among Aboriginal and Torres Strait Islander Australians.. <i>Addiction Science & Clinical Practice</i> , 2022 , 17, 17	4.1	0
154	The impact of opioid agonist treatment on fatal and non-fatal drug overdose among people with a history of opioid dependence in NSW, Australia, 2001-2018: Findings from the OATS retrospective linkage study.. <i>Drug and Alcohol Dependence</i> , 2022 , 236, 109464	4.9	1
153	Perceptions of injectable opioid agonist treatment (iOAT) among people who regularly use opioids in Australia: findings from a cross-sectional study in three Australian cities. <i>Addiction</i> , 2021 , 116, 1482-1494	4.6	1
152	Brief Intervention for Illicit Drug Use 2021 , 655-671		
151	Revision of the Australian guidelines to reduce health risks from drinking alcohol. <i>Medical Journal of Australia</i> , 2021 , 215, 518	4	2
150	Outcomes of a single-arm implementation trial of extended-release subcutaneous buprenorphine depot injections in people with opioid dependence. <i>International Journal of Drug Policy</i> , 2021 , 100, 103492	5.5	2
149	The effect of person, treatment and prescriber characteristics on retention in opioid agonist treatment: a 15-year retrospective cohort study. <i>Addiction</i> , 2021 , 116, 3139-3152	4.6	3
148	Data Resource Profile: The Opioid Agonist Treatment and Safety (OATS) Study, New South Wales, Australia. <i>International Journal of Epidemiology</i> , 2021 , 49, 1774-1775	7.8	4
147	Quality of life as a predictor of time to heroin relapse among male residents following release from compulsory rehabilitation centres in Vietnam. <i>Drug and Alcohol Review</i> , 2021 , 40, 296-306	3.2	3
146	Hospitalisations for non-fatal overdose among people with a history of opioid dependence in New South Wales, Australia, 2001-2018: Findings from the OATS retrospective cohort study. <i>Drug and Alcohol Dependence</i> , 2021 , 218, 108354	4.9	1
145	Retention of opioid agonist treatment prescribers across New South Wales, Australia, 2001-2018: Implications for treatment systems and potential impact on client outcomes. <i>Drug and Alcohol Dependence</i> , 2021 , 219, 108464	4.9	2
144	A clinical research priority setting study for issues related to the use of methamphetamine and emerging drugs of concern in Australia. <i>Drug and Alcohol Review</i> , 2021 ,	3.2	1
143	Global opioid agonist treatment: a review of clinical practices by country. <i>Addiction</i> , 2020 , 115, 2243-2254	4.6	21
142	Perceptions of extended-release buprenorphine injections for opioid use disorder among people who regularly use opioids in Australia. <i>Addiction</i> , 2020 , 115, 1295-1305	4.6	29
141	The contribution of methamphetamine use to crime: Evidence from Australian longitudinal data. <i>Drug and Alcohol Dependence</i> , 2020 , 216, 108262	4.9	5
140	Open-label, multicentre, single-arm trial of monthly injections of depot buprenorphine in people with opioid dependence: protocol for the CoLAB study. <i>BMJ Open</i> , 2020 , 10, e034389	3	6
139	Response to commentaries. <i>Addiction</i> , 2019 , 114, 1357-1358	4.6	

138	Responding to global stimulant use: challenges and opportunities. <i>Lancet, The</i> , 2019 , 394, 1652-1667	4.0	83
137	Measurement-based care using DSM-5 for opioid use disorder: can we make opioid medication treatment more effective?. <i>Addiction</i> , 2019 , 114, 1346-1353	4.6	24
136	Transferring Patients From Methadone to Buprenorphine: The Feasibility and Evaluation of Practice Guidelines. <i>Journal of Addiction Medicine</i> , 2018 , 12, 234-240	3.8	12
135	Outcomes of compulsory detention compared to community-based voluntary methadone maintenance treatment in Vietnam. <i>Journal of Substance Abuse Treatment</i> , 2018 , 87, 9-15	4.2	10
134	The effect of a potentially tamper-resistant oxycodone formulation on opioid use and harm: main findings of the National Opioid Medications Abuse Deterrence (NOMAD) study. <i>Lancet Psychiatry, the</i> , 2018 , 5, 155-166	23.3	22
133	Global statistics on alcohol, tobacco and illicit drug use: 2017 status report. <i>Addiction</i> , 2018 , 113, 1905-1926	12.6	371
132	LiMA: a study protocol for a randomised, double-blind, placebo controlled trial of lisdexamfetamine for the treatment of methamphetamine dependence. <i>BMJ Open</i> , 2018 , 8, e020723	3	9
131	Improving outcomes in the treatment of opioid dependence (IOTOD): reflections on the impact of a medical education initiative on healthcare professionals' attitudes and clinical practice. <i>Journal of European CME</i> , 2018 , 7, 1506197	0.6	0
130	Latent Psychotic Symptom Profiles Amongst People Who Use Methamphetamine: What Do They Tell Us About Existing Diagnostic Categories?. <i>Frontiers in Psychiatry</i> , 2018 , 9, 578	5	6
129	Participant perspectives on the Australian WHO ASSIST Phase III brief intervention for illicit drug use in a primary healthcare setting. <i>Australian Journal of Primary Health</i> , 2018 , 24, 518-523	1.4	
128	A randomised controlled trial of a brief intervention for illicit drug use linked to ASSIST screening in a primary healthcare setting: results from the Australian component of the World Health Organization Phase III ASSIST studies. <i>Australian Journal of Primary Health</i> , 2018 , 24, 149-154	1.4	3
127	Using routinely collected data to understand and predict adverse outcomes in opioid agonist treatment: Protocol for the Opioid Agonist Treatment Safety (OATS) Study. <i>BMJ Open</i> , 2018 , 8, e025204 ³		16
126	Identifying substance misuse in primary care: TAPS Tool compared to the WHO ASSIST. <i>Journal of Substance Abuse Treatment</i> , 2017 , 76, 69-76	4.2	9
125	Opioid antagonists with minimal sedation for opioid withdrawal. <i>The Cochrane Library</i> , 2017 , 5, CD002023 ²	3.2	18
124	Feasibility of Studying a Brief Intervention to Help Chinese Villagers with Problem Alcohol Use After an Earthquake. <i>Alcohol and Alcoholism</i> , 2017 , 52, 472-476	3.5	4
123	Buprenorphine for managing opioid withdrawal. <i>The Cochrane Library</i> , 2017 , 2, CD002025	5.2	49
122	Strengthening advocacy efforts with empirical evidence: A case example of the conduct, uptake and utilisation of research in drug policy decision-making in Vietnam. <i>International Journal of Drug Policy</i> , 2017 , 49, 41-47	5.5	1
121	The political and scientific challenges in evaluating compulsory drug treatment centers in Southeast Asia. <i>Harm Reduction Journal</i> , 2017 , 14, 2	4.6	14

120	The extramedical use and diversion of opioid substitution medications and other medications in prison settings in Australia following the introduction of buprenorphine-naloxone film. <i>Drug and Alcohol Review</i> , 2016 , 35, 76-82	3.2	14
119	Correlates of transient versus persistent psychotic symptoms among dependent methamphetamine users. <i>Psychiatry Research</i> , 2016 , 238, 166-171	9.9	22
118	Analysis of qualitative data from the investigation study in pregnancy of the ASSIST Version 3.0 (the Alcohol, Smoking and Substance Involvement Screening Test). <i>Midwifery</i> , 2016 , 34, 183-197	2.8	6
117	The Ultrarapid Alcohol, Smoking, and Substance Involvement Screening Test (ASSIST-Lite) and Implications for Neuropathology 2016 , 649-659		
116	Ethical considerations when researching with pregnant substance users and implications for practice. <i>Addictive Behaviors</i> , 2016 , 60, 242-3	4.2	2
115	Cost-effectiveness of center-based compulsory rehabilitation compared to community-based voluntary methadone maintenance treatment in Hai Phong City, Vietnam. <i>Drug and Alcohol Dependence</i> , 2016 , 168, 147-155	4.9	17
114	Alpha-2 adrenergic agonists for the management of opioid withdrawal. <i>The Cochrane Library</i> , 2016 , CD002524	3.2	51
113	Same-day use of opioids and other central nervous system depressants amongst people who tamper with pharmaceutical opioids: A retrospective 7-day diary study. <i>Drug and Alcohol Dependence</i> , 2016 , 166, 125-33	4.9	7
112	Diversion and injection of buprenorphine-naloxone film two years post-introduction in Australia. <i>Drug and Alcohol Review</i> , 2016 , 35, 83-91	3.2	8
111	The introduction of a potentially abuse deterrent oxycodone formulation: Early findings from the Australian National Opioid Medications Abuse Deterrence (NOMAD) study. <i>Drug and Alcohol Dependence</i> , 2015 , 151, 56-67	4.9	27
110	Evaluating the potential impact of a reformulated version of oxycodone upon tampering, non-adherence and diversion of opioids: the National Opioid Medications Abuse Deterrence (NOMAD) study protocol. <i>Addiction</i> , 2015 , 110, 226-37	4.6	18
109	Global statistics on addictive behaviours: 2014 status report. <i>Addiction</i> , 2015 , 110, 904-19	4.6	238
108	The characteristics of a cohort who tamper with prescribed and diverted opioid medications. <i>Journal of Substance Abuse Treatment</i> , 2015 , 58, 51-61	4.2	17
107	Facilitating a transition from compulsory detention of people who use drugs towards voluntary community-based drug dependence treatment and support services in Asia. <i>Harm Reduction Journal</i> , 2015 , 12, 31	4.6	21
106	The introduction of buprenorphine-naloxone film in opioid substitution therapy in Australia: Uptake and issues arising from changing buprenorphine formulations. <i>Drug and Alcohol Review</i> , 2015 , 34, 603-10	3.2	7
105	Injecting buprenorphine-naloxone film: Findings from an explorative qualitative study. <i>Drug and Alcohol Review</i> , 2015 , 34, 623-9	3.2	5
104	Jurisdictional differences in opioid use, other licit and illicit drug use, and harms associated with substance use among people who tamper with pharmaceutical opioids. <i>Drug and Alcohol Review</i> , 2015 , 34, 611-22	3.2	10
103	A typology of people who tamper with pharmaceutical opioids: responses to introduction of a tamper-resistant formulation of controlled-release oxycodone. <i>Pharmacoepidemiology and Drug Safety</i> , 2015 , 24, 1321-33	2.6	4

102 Brief Intervention for Illicit Drug Users **2015**, 293-312

101	The diversion and injection of a buprenorphine-naloxone soluble film formulation. <i>Drug and Alcohol Dependence</i> , 2014 , 136, 21-7	4.9	39
100	Development of the Addiction Dimensions for Assessment and Personalised Treatment (ADAPT). <i>Drug and Alcohol Dependence</i> , 2014 , 139, 121-31	4.9	18
99	Alpha2-adrenergic agonists for the management of opioid withdrawal. <i>Cochrane Database of Systematic Reviews</i> , 2014 , CD002024		39
98	Pharmacogenomics of methadone maintenance treatment. <i>Pharmacogenomics</i> , 2014 , 15, 1007-27	2.6	33
97	A latent class analysis of self-reported clinical indicators of psychosocial stability and adherence among opioid substitution therapy patients: do stable patients receive more unsupervised doses?. <i>Drug and Alcohol Dependence</i> , 2014 , 142, 46-55	4.9	11
96	Pharmacotherapies for cannabis dependence. <i>The Cochrane Library</i> , 2014 , CD008940	5.2	70
95	Ultra-rapid screening for substance-use disorders: the Alcohol, Smoking and Substance Involvement Screening Test (ASSIST-Lite). <i>Drug and Alcohol Dependence</i> , 2013 , 132, 352-61	4.9	67
94	A randomised controlled trial of sublingual buprenorphine-naloxone film versus tablets in the management of opioid dependence. <i>Drug and Alcohol Dependence</i> , 2013 , 131, 119-26	4.9	34
93	Methadone at tapered doses for the management of opioid withdrawal. <i>The Cochrane Library</i> , 2013 , CD003409	5.2	56
92	Dose-related psychotic symptoms in chronic methamphetamine users: evidence from a prospective longitudinal study. <i>JAMA Psychiatry</i> , 2013 , 70, 319-24	14.5	129
91	Investigation of the Alcohol, Smoking, and Substance Involvement Screening Test (the ASSIST) Version 3.0 in Pregnancy. <i>Addictive Disorders and Their Treatment</i> , 2013 , 12, 123-135	0.5	9
90	Evaluating the impact of community-based treatment options on methamphetamine use: findings from the Methamphetamine Treatment Evaluation Study (MATES). <i>Addiction</i> , 2012 , 107, 1998-2008	4.6	90
89	Predictive factors for treatment retention in methadone programs in Indonesia. <i>Journal of Substance Abuse Treatment</i> , 2012 , 42, 239-46	4.2	47
88	Drug policy in Vietnam: a decade of change?. <i>International Journal of Drug Policy</i> , 2012 , 23, 319-26	5.5	37
87	A randomized controlled trial of a brief intervention for illicit drugs linked to the Alcohol, Smoking and Substance Involvement Screening Test (ASSIST) in clients recruited from primary health-care settings in four countries. <i>Addiction</i> , 2012 , 107, 957-66	4.6	136
86	Screening for use of alcohol, tobacco and cannabis in pregnancy using self-report tools. <i>Journal of Developmental Origins of Health and Disease</i> , 2012 , 3, 216-23	2.4	
85	Cochrane systematic reviews in the field of addiction: what's there and what should be. <i>Drug and Alcohol Dependence</i> , 2011 , 113, 96-103	4.9	23

84	Post-marketing surveillance of buprenorphine-naloxone in Australia: diversion, injection and adherence with supervised dosing. <i>Drug and Alcohol Dependence</i> , 2011 , 118, 265-73	4.9	53
83	Comparisons of methamphetamine psychotic and schizophrenic symptoms: a differential item functioning analysis. <i>Progress in Neuro-Psychopharmacology and Biological Psychiatry</i> , 2011 , 35, 959-64	5.5	62
82	Oral substitution treatment of injecting opioid users for prevention of HIV infection. <i>The Cochrane Library</i> , 2011 , CD004145	5.2	170
81	Prescribers' perceptions of the diversion and injection of medication by opioid substitution treatment patients. <i>Drug and Alcohol Review</i> , 2011 , 30, 613-20	3.2	16
80	Methamphetamine Psychosis in Australia, Philippines, and Thailand. <i>Addictive Disorders and Their Treatment</i> , 2010 , 9, 143-149	0.5	9
79	Mood Disturbance and Withdrawal Severity in Substitution Treatment for Opioid Dependence. <i>Addictive Disorders and Their Treatment</i> , 2010 , 9, 1-7	0.5	
78	United Nations Office on Drugs and Crime International Network of Drug Dependence Treatment and Rehabilitation Resource Centres: Treatnet. <i>Substance Abuse</i> , 2010 , 31, 251-63	3.8	13
77	Opioid antagonists under heavy sedation or anaesthesia for opioid withdrawal. <i>The Cochrane Library</i> , 2010 , CD002022	5.2	28
76	Buprenorphine for the management of opioid withdrawal. <i>Cochrane Database of Systematic Reviews</i> , 2009 , CD002025		76
75	Alpha2-adrenergic agonists for the management of opioid withdrawal. <i>Cochrane Database of Systematic Reviews</i> , 2009 , CD002024		31
74	Opioid antagonists with minimal sedation for opioid withdrawal. <i>Cochrane Database of Systematic Reviews</i> , 2009 , CD002021		25
73	Injection of medications used in opioid substitution treatment in Australia after the introduction of a mixed partial agonist-antagonist formulation. <i>Medical Journal of Australia</i> , 2009 , 191, 161-5	4	33
72	Pregnancy-related changes in tobacco, alcohol and cannabis use reported by antenatal patients at two public hospitals in South Australia. <i>Australian and New Zealand Journal of Obstetrics and Gynaecology</i> , 2008 , 48, 248-54	1.7	29
71	Exposure to opioid maintenance treatment reduces long-term mortality. <i>Addiction</i> , 2008 , 103, 462-8	4.6	136
70	Validation of the Alcohol, Smoking And Substance Involvement Screening Test (ASSIST). <i>Addiction</i> , 2008 , 103, 1039-47	4.6	626
69	Key findings from the WHO collaborative study on substitution therapy for opioid dependence and HIV/AIDS. <i>Addiction</i> , 2008 , 103, 1484-92	4.6	174
68	Flexible dosing of tincture of opium in the management of opioid withdrawal: pharmacokinetics and pharmacodynamics. <i>British Journal of Clinical Pharmacology</i> , 2008 , 66, 640-7	3.8	16
67	Substitution treatment of injecting opioid users for prevention of HIV infection. <i>Cochrane Database of Systematic Reviews</i> , 2008 , CD004145		88

66	The rise of methamphetamine in Southeast and East Asia. <i>Drug and Alcohol Review</i> , 2008 , 27, 220-8	3.2	107
65	Buprenorphine for the management of opioid withdrawal. <i>Cochrane Database of Systematic Reviews</i> , 2006 , CD002025		50
64	A cost-effectiveness analysis of heroin detoxification methods in the Australian National Evaluation of Pharmacotherapies for Opioid Dependence (NEPOD). <i>Addictive Behaviors</i> , 2006 , 31, 371-87	4.2	19
63	One year outcomes for heroin dependence: findings from the Australian Treatment Outcome Study (ATOS). <i>Drug and Alcohol Dependence</i> , 2006 , 83, 174-80	4.9	102
62	Opioid antagonists with minimal sedation for opioid withdrawal. <i>Cochrane Database of Systematic Reviews</i> , 2006 , CD002021		8
61	Opioid antagonists under heavy sedation or anaesthesia for opioid withdrawal. <i>Cochrane Database of Systematic Reviews</i> , 2006 , CD002022		8
60	The place of detoxification in treatment of opioid dependence. <i>Current Opinion in Psychiatry</i> , 2006 , 19, 266-70	4.9	25
59	Short-term Outcomes for the Treatment of Heroin Dependence. <i>Addictive Disorders and Their Treatment</i> , 2006 , 5, 133-143	0.5	22
58	Maintenance Pharmacotherapy for Opioid Dependence and SF-36 Health Status: A Comparison With General Population Norms and Other Chronic Disorders. <i>Addictive Disorders and Their Treatment</i> , 2006 , 5, 155-164	0.5	10
57	Abstinence-orientated buprenorphine replacement therapy for young adults in out-patient counselling. <i>Drug and Alcohol Review</i> , 2006 , 25, 123-30	3.2	9
56	Brief report: Methadone treatment of injecting opioid users for prevention of HIV infection. <i>Journal of General Internal Medicine</i> , 2006 , 21, 193-5	4	48
55	Factors associated with 12 months continuous heroin abstinence: findings from the Australian Treatment Outcome Study (ATOS). <i>Journal of Substance Abuse Treatment</i> , 2005 , 28, 255-63	4.2	68
54	Short-term outcomes of five heroin detoxification methods in the Australian NEPOD Project. <i>Addictive Behaviors</i> , 2005 , 30, 443-56	4.2	21
53	Methadone at tapered doses for the management of opioid withdrawal. <i>Cochrane Database of Systematic Reviews</i> , 2005 , CD003409		50
52	The first methadone clinic in Beijing. <i>Drug and Alcohol Review</i> , 2005 , 24, 285-7	3.2	6
51	Validation of the World Health Organization Alcohol, Smoking and Substance Involvement Screening Test (ASSIST): report of results from the Australian site. <i>Drug and Alcohol Review</i> , 2005 , 24, 217-26	3.2	169
50	The characteristics of heroin users entering treatment: findings from the Australian treatment outcome study (ATOS). <i>Drug and Alcohol Review</i> , 2005 , 24, 411-8	3.2	179
49	Effectiveness of drug dependence treatment in HIV prevention. <i>International Journal of Drug Policy</i> , 2005 , 16, 67-75	5.5	49

48	Comparison of tincture of opium and methadone to control opioid withdrawal in a Thai treatment centre. <i>British Journal of Clinical Pharmacology</i> , 2004 , 58, 536-41	3.8	15
47	Heroin users in Australia: population trends. <i>Drug and Alcohol Review</i> , 2004 , 23, 107-16	3.2	12
46	Asia Pacific Column. Announcement of column on capacity building in the Asia Pacific region. <i>Drug and Alcohol Review</i> , 2004 , 23, 133-4	3.2	
45	Impact of the heroin drought on patterns of drug use and drug-related harms. <i>Drug and Alcohol Review</i> , 2004 , 23, 143-50	3.2	22
44	Amphetamines in Asia: the value of information networks. <i>Drug and Alcohol Review</i> , 2004 , 23, 235-7	3.2	2
43	Substance use and treatment options in Cambodia. <i>Drug and Alcohol Review</i> , 2004 , 23, 365-7	3.2	2
42	Alpha2 adrenergic agonists for the management of opioid withdrawal. <i>Cochrane Database of Systematic Reviews</i> , 2004 , CD002024		15
41	Psychotic symptoms in methamphetamine psychotic in-patients. <i>International Journal of Neuropsychopharmacology</i> , 2003 , 6, 347-52	5.8	140
40	Antagonist-precipitated heroin withdrawal under anaesthetic prior to maintenance naltrexone treatment: determinants of withdrawal severity. <i>Drug and Alcohol Review</i> , 2003 , 22, 425-31	3.2	8
39	Prevalence and correlates of intravenous methadone syrup administration in Adelaide, Australia. <i>Addiction</i> , 2003 , 98, 413-8	4.6	31
38	Buprenorphine versus methadone maintenance therapy: a randomized double-blind trial with 405 opioid-dependent patients. <i>Addiction</i> , 2003 , 98, 441-52	4.6	206
37	Buprenorphine versus methadone maintenance: a cost-effectiveness analysis. <i>Drug and Alcohol Dependence</i> , 2003 , 71, 295-302	4.9	86
36	Alpha2-adrenergic agonists in opioid withdrawal. <i>Addiction</i> , 2002 , 97, 49-58	4.6	53
35	The Alcohol, Smoking and Substance Involvement Screening Test (ASSIST): development, reliability and feasibility. <i>Addiction</i> , 2002 , 97, 1183-94	4.6	972
34	Methamphetamine: drug use and psychoses becomes a major public health issue in the Asia Pacific region. <i>Addiction</i> , 2002 , 97, 771-2	4.6	91
33	The health effects of ecstasy: a literature review. <i>Drug and Alcohol Review</i> , 2002 , 21, 53-63	3.2	104
32	Accidental Fatalities Among Heroin Users in South Australia, 1994-1997: Toxicological Findings and Circumstances of Death. <i>Addiction Research and Theory</i> , 2002 , 10, 335-346	2.6	14
31	Harm Minimization in a Prohibition Context: Australia. <i>Annals of the American Academy of Political and Social Science</i> , 2002 , 582, 80-93	2.8	12

30	Comment on: Doherty et al., Hyperalgesic responses in methadone maintenance patients (Pain 2001;90;918). <i>Pain</i> , 2002 , 99, 609-610	8	1
29	Relationship between LAAM-methadone preference and treatment outcomes. <i>Drug and Alcohol Dependence</i> , 2002 , 66, 295-301	4.9	18
28	A comparison of antagonist-precipitated withdrawal under anesthesia to standard inpatient withdrawal as a precursor to maintenance naltrexone treatment in heroin users: outcomes at 6 and 12 months. <i>Drug and Alcohol Dependence</i> , 2002 , 68, 5-14	4.9	37
27	Which substitution pharmacotherapy is most effective in treating opioid dependence?. <i>Medical Journal of Australia</i> , 2002 , 176, 493-4	4	
26	Hyperalgesic responses in methadone maintenance patients. <i>Pain</i> , 2001 , 90, 91-6	8	215
25	Cochrane Drugs and Alcohol Group: the development of systematic reviews of treatment outcome. <i>Alcohol and Alcoholism</i> , 2001 , 36, 109-11	3.5	1
24	Overdose Among Heroin Users: Evaluation of an Intervention in South Australia. <i>Addiction Research and Theory</i> , 2001 , 9, 481-501	2.6	14
23	Systematic review processes and the management of opioid withdrawal. <i>Australian and New Zealand Journal of Public Health</i> , 2000 , 24, 427-31	2.3	5
22	The management of opioid withdrawal. <i>Drug and Alcohol Review</i> , 2000 , 19, 309-318	3.2	14
21	A Training, Authorisation and Review Process for Methadone Prescribers. <i>Journal of Maintenance in the Addictions</i> , 2000 , 1, 15-25		2
20	The Impact of Cannabis Decriminalisation in Australia and the United States. <i>Journal of Public Health Policy</i> , 2000 , 21, 157	2.9	58
19	A review of biological indicators of illicit drug use, practical considerations and clinical usefulness. <i>Addiction</i> , 1999 , 94, 1279-98	4.6	133
18	Characteristics of amphetamine users seeking information, help and treatment in Adelaide, South Australia. <i>Drug and Alcohol Review</i> , 1999 , 18, 63-73	3.2	17
17	Laws applying to minor cannabis offences in Australia and their evaluation. <i>International Journal of Drug Policy</i> , 1999 , 10, 299-303	5.5	4
16	Physical and mental health problems in amphetamine users from metropolitan Adelaide, Australia. <i>Drug and Alcohol Review</i> , 1998 , 17, 187-95	3.2	30
15	Correlates of retention on the South Australian Methadone Program 1981-91. <i>Australian and New Zealand Journal of Public Health</i> , 1998 , 22, 771-6	2.3	8
14	Experience of non-fatal overdose among heroin users in Adelaide, Australia: circumstances and risk perceptions. <i>Addiction</i> , 1998 , 93, 701-11	4.6	154
13	Therapeutic use of cannabis: clarifying the debate. <i>Drug and Alcohol Review</i> , 1998 , 17, 445-52	3.2	3

12	HIV prevalence and risk behaviour in needle exchange attenders: a national study. <i>Medical Journal of Australia</i> , 1997 , 166, 237-240	4	63
11	Improvements in retention rates and changes in client group with methadone maintenance streaming. <i>Drug and Alcohol Review</i> , 1996 , 15, 83-8	3.2	16
10	HIV infection among injecting drug users in the South Australian methadone program. <i>Medical Journal of Australia</i> , 1995 , 162, 242-4	4	4
9	In-patient treatment for the alcohol-dependent person: a public health perspective. <i>Drug and Alcohol Review</i> , 1994 , 13, 195-202	3.2	3
8	Injecting behaviour and risky needle use amongst methadone maintenance clients. <i>Drug and Alcohol Dependence</i> , 1994 , 34, 113-9	4.9	13
7	Hepatitis C and the history of injecting drug use in South Australia. <i>Medical Journal of Australia</i> , 1994 , 161, 286; author reply 287	4	7
6	The prescription of methadone for opiate dependence in Australia, 1985-1991. <i>Medical Journal of Australia</i> , 1993 , 159, 107-8	4	6
5	Bloody needles. <i>Aids</i> , 1991 , 5, 1025-1028	3.5	38
4	HIV prevalence and risk behaviours for HIV transmission in South Australian prisons. <i>Aids</i> , 1991 , 5, 845-51	3.5	29
3	Preventing human immunodeficiency virus (HIV) infection among prisoners: prisoners' knowledge of HIV and their attitudes to options for prevention. <i>Community Health Studies</i> , 1990 , 14, 61-4		1
2	Risk of transmission of the human immunodeficiency virus in the prison setting. <i>Medical Journal of Australia</i> , 1990 , 153, 434-434	4	1
1	Risk of transmission of the human immunodeficiency virus in the prison setting. <i>Medical Journal of Australia</i> , 1989 , 150, 722-722	4	10